Security key
75629V104
RECURSION PHARMACEUTICALS, INC. - Common Stock (RXRX)
CUSIP: 75629V104
Q3 2024 13F Holders as of 30 Sep 2024
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 264,392,743
- Total 13F value
- $1,743,289,324
- Share change
- +9,331,280
- Put/Call ratio
- 172%
- SEC-reported price per share
- $6.59
- Number of holders
- 262
- Value change
- +$54,064,157
- Number of buys
- 150
- Number of sells
- 95
- Shares outstanding
- 525,448,476
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2024
Institutions
262
Top holders
10
RXRX full security history
Ownership snapshot
Full 13F holder table
RECURSION PHARMACEUTICALS, INC. SEC filings
RECURSION PHARMACEUTICALS, INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of RXRX - RECURSION PHARMACEUTICALS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VIKING GLOBAL INVESTORS LP
Disclosed value leader
Mubadala Investment Co PJSC
Comparable rows
15/15
Latest evidence
30 Jun 2024
13F
3/4/5
Lead comparable stake: 28%
Showing 1-6 of 15 holder rows.
Quick read
VIKING GLOBAL INVESTORS LP leads the comparable SEC ownership view at 28%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VIKING GLOBAL INVESTORS LP's linked filing trail.
Comparable ownership
Top 5
VIKING GLOBAL INVESTORS LP
28%
Anchorage Capital Group, L.L.C.
13%
GLENVIEW CAPITAL MANAGEMENT, LLC
5.1%
SB INVESTMENT ADVISERS (UK) LTD
4.7%
D. E. Shaw & Co., Inc.
3.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP |
13F
Company
|
28%
|
$47,833,358
143,085,126 shares
|
— | 30 Jun 2024 |
| Anchorage Capital Group, L.L.C. |
13F
Company
|
13%
|
$23,352,390
69,854,593 shares
|
— | 30 Jun 2024 |
| GLENVIEW CAPITAL MANAGEMENT, LLC |
13F
Company
|
5.1%
|
$8,858,950
26,500,000 shares
|
— | 30 Jun 2024 |
| SB INVESTMENT ADVISERS (UK) LTD |
13F
Company
|
4.7%
|
$8,166,679
24,429,191 shares
|
— | 30 Jun 2024 |
| D. E. Shaw & Co., Inc. |
13F
Company
|
3.4%
|
$5,802,234
17,356,369 shares
|
— | 30 Jun 2024 |
| Qube Research & Technologies Ltd |
13F
Company
|
3%
|
$5,185,762
15,512,302 shares
|
— | 30 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
262
Shares
264,392,743
Rows available
262
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
264
Q3 2024 holders
262
Holder diff
-2
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 value | Q3 2024 value | Value change | Value Chg % |
|---|